Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | AFM24 + SNK01 |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
AFM24 | AFM-24|AFM 24 | EGFR Antibody 61 | AFM24 is a bispecific antibody that targets EGFR and CD16A, which may result in an anti-tumor immune response against tumor cells expressing Egfr (Cancer Res 2022;82(12_Suppl):Abstract nr CT149, PMID: 34325617). | |
SNK01 | SNK-01|SNK 01 | SNK01 is a modified autologous natural killer cell therapy, which potentially increases cytotoxicity against tumor cells (J. of Clin. Onc. 2020 38:15_suppl, e15024). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05099549 | Phase Ib/II | AFM24 + SNK01 | Safety, Tolerability, and Anti-Tumor Activity of AFM24 in Combination With SNK01 in Subjects With Advanced/Metastatic EGFR-Expressing Cancers | Terminated | USA | 0 |